Rachel Haurwitz | President and Chief Executive Officer
Caribou Biosciences

Rachel Haurwitz, President and Chief Executive Officer, Caribou Biosciences

Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.


Day 2 Orphan 15th Nov @ 14:35

The potential of gene editing therapies for orphan drugs: Harnessing CRISPR technology for rare disease drug development

  • The current state of CRISPR gene editing technology  
  • Employing revolutionary gene editing technology to treat monogenic rare diseases
  • The opportunities and the challenges 

back to speakers